Evidence map›Paper›PMID 32683598›Full record

ArticleInternational journal of hematology2020

Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan.

Akihiko Yokohama, Yoshiki Okuyama, Yasunori Ueda, Masumi Itoh, Shin-Ichiro Fujiwara, Yuichi Hasegawa, Kazuhiro Nagai, Kimika Arakawa, Koji Miyazaki, Masanori Makita and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 1 country.

Akihiko YokohamaDivision of Blood Transfusion Service, Gunma University Hospital, Gunma University School of Medicine , 3-39-15 Showa, Maebashi, Gunma, 371-8511, Japan. ayoko@gunma-u.ac.jp.ORCID http://orcid.org/0000-0001-8514-086X
Yoshiki OkuyamaDivision of Transfusion and Cell Therapy, Tokyo Metropolitan Komagome Hospital, Bunkyo, Tokyo, Japan.
Yasunori UedaDepartment of Hematology and Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
Masumi ItohClinical Laboratory, Narita Red Cross Hospital, Narita, Chiba, Japan.
Shin-Ichiro FujiwaraClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Yuichi HasegawaClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Kazuhiro NagaiTransfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
Kimika ArakawaDivision of Clinical Laboratory, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Koji MiyazakiDepartment of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Masanori MakitaDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Mai WatanabeDepartment of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan.
Kazuhiko IkedaDepartment of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.
Asashi TanakaClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Keizo FujinoClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Mayumi MatsumotoClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Shigeyoshi MakinoClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Shuichi KinoClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Akihiro TakeshitaClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Kazuo MuroiClinical Study Supporting Committee, The Japan Society of Transfusion Medicine and Cell Therapy, Tokyo, Japan.
Jichi Medical University · JPFukushima Medical University · JPGunma University · JPHamamatsu University School of Medicine · JPJapanese Red Cross Narita Hospital · JPKitasato University · JPKurashiki Central Hospital · JPNagasaki University Hospital · JPNational Hospital Organization · JPNational Kyushu Medical Center · JPOsaka City University Hospital · JPSendai Medical Center · JPShinko Hospital · JPTokyo Medical University Hachioji Medical Center · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JPUniversity of Tsukuba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hemoglobin (Hb) threshold level of 7 g/dL has been proposed for red blood cell (RBC) transfusion in patients with chronic anemia in the Japanese guideline since 2005. However, Hb thresholds for hematological diseases in clinical practice and factors responsible for higher Hb thresholds remain unclear. Hb thresholds were collected for patients with hematological diseases from 32 Japanese teaching hospitals. Uni- and multivariate analyses were used to analyze relationships between Hb threshold level and various patient and hospital factors. In total, 4996 units of RBC were transfused to 1054 patients with hematological diseases in 2421 transfusions. Median age was 68 years. Myelodysplastic syndrome was the most frequent diagnosis. Overall median Hb threshold level was 6.9 g/dL. Multivariate linear regression analysis detected the following variables associated with Hb threshold level: hospital; cardiovascular disease; symptomatic anemia; and hematopoietic stem cell transplantation. Hospital was the most significant factor. Collectively, median Hb threshold level in clinical practice in Japan was similar to the guidelines. Higher Hb threshold level depended on the hospitals at which the transfusions were performed as well as patient condition. Educational approaches directed toward hospitals may be useful to promote transfusion guidelines.

Indexed as

HemoglobinsHospitals, TeachingAgedDifferential ThresholdErythrocyte TransfusionFemaleHematologic DiseasesHumansJapanMaleMiddle AgedMultivariate AnalysisMyelodysplastic SyndromesPractice Guidelines as TopicSurveys and QuestionnairesHemoglobinsGuidelineHematological diseaseHemoglobin threshold levelRed blood cell transfusion

Identifiers

PMID32683598
OpenAlexW3042422365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.